✦ LIBER ✦

Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B

✍ Scribed by Stefan Zeuzem; Edward Gane; Yun-Fan Liaw; Seng G. Lim; Adrian DiBisceglie; Maria Buti; Anuchit Chutaputti; Jens Rasenack; Jinlin Hou; Christopher O’Brien; Tuan T. Nguyen; Jidong Jia; Thierry Poynard; Bruce Belanger; Weibin Bao; Nikolai V. Naoumov

Book ID: 116651819
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 483 KB
Volume: 51
Category: Article
ISSN: 0168-8278
DOI: 10.1016/j.jhep.2008.12.019

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Early on-treatment prediction of respons

Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels

✍ Vincent Rijckborst; Bettina E. Hansen; Yilmaz Cakaloglu; Peter Ferenci; Fehmi Ta 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 189 KB 👁 2 views

Ferenci is a consultant for, advises, is on the speakers' bureau of, and received grants from Roche. Dr. Janssen is a consultant for and received grants from Roche, Bristol-Myers Squibb, Schering-Plough, Novartis, and Gilead. Dr. Flisiak received grants from Roche.

The impact of steatosis on baseline char

The impact of steatosis on baseline characteristic and end of treatment response for chronic hepatitis (C) genotype 4 patients treated with interferon

✍ G. Esmat; M.K. Mohamed; M. Abdel Hamid; K. Zalata; H. Khatab; M. El Batanony; A. 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 165 KB

747 Effect of core promoter/precore muta

747 Effect of core promoter/precore mutation pattern and early virologic response on efficacy outcomes with telbivudine in HBeAg-negative chronic hepatitis B

✍ N. Naoumov; C.L. Lai; E. Gane; Y.E. Liaw; S. Thongsawat; Y. Wang; E.J. Heathcote 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 253 KB

753 BASELINE HBsAg PREDICTS HBsAg LOSS A

753 BASELINE HBsAg PREDICTS HBsAg LOSS AFTER 2 YEARS OF TREATMENT-FREE FOLLOW-UP IN CHRONIC HEPATITIS B PATIENTS TREATED WITH PEGINTERFERON alfa-2a AND ADEFOVIR

✍ Jansen, L.; Takkenberg, R.B.; de Niet, A.; Zaaijer, H.L.; Weegink, C.J.; Terpstr 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 53 KB

[513] EFFICACY OF TELBIVUDINE VS LAMIVUD

[513] EFFICACY OF TELBIVUDINE VS LAMIVUDINE AT 2 YEARS IN PATIENTS WITH HBeAg-POSITIVE CHRONIC HEPATITIS B WHO ARE ELIGIBLE FOR TREATMENT BASED ON GUIDELINES

✍ J. Rasenack; T. Poynard; C.-L. Lai; E. Gane; N.A. Brown; J. Heathcote 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 144 KB

1006 HBSAG KINETICS OF DECAY AND BASELIN

1006 HBSAG KINETICS OF DECAY AND BASELINE CHARACTERISTICS OF HBEAG-POSITIVE PATIENTS WITH CHRONIC HEPATITIS B FOLLOWING 3 YEARS OF TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT

✍ Gane, E.; Heathcote, E.J.; Marcellin, P.; Dusheiko, G.; Jacobson, I.; de Man, R. 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 53 KB

Baseline characteristics and early on-treatment response predict the outcomes of 2&#xa0;years of telbivudine treatment of chronic hepatitis B

Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B